

Santen Announces Share Buyback

Santen Pharmaceutical Co., Ltd. (Head Office: Osaka; President and CEO: Shigeo Taniuchi; hereafter, Santen) announced that its Board of Directors resolved today to repurchase its own shares in accordance with Article 156 of the Companies Act (Japan), as applied pursuant to Article 165, paragraph 3.

This repurchase is implemented in accordance with the announcement today of the “Notice on the Formulation of a Share Buyback Policy”.

1. Reasons for Repurchase of Own Shares

To enhance capital efficiency and improve return of profits.

2. Details of Repurchase

(1) Class of shares to be repurchased	Common shares
(2) Total number of shares to be repurchased	12,500,000 shares (maximum) *Representing 3.1% of the total number of shares outstanding (excluding treasury shares)
(3) Total amount of repurchase	15.0 billion yen (maximum)
(4) Period of repurchase	May 11, 2022 to September 30, 2022
(5) Method of repurchase	Open-market repurchase through discretionary investment contract
(6) Other	After repurchase, Santen plans to cancel the repurchased shares within the fiscal year ending March 2023 by its Board of Directors resolution in accordance with Article 178 of the Companies Act (Japan).

(Reference) Treasury Shares Information as of 31 March, 2022

Total number of shares outstanding (excluding treasury shares)	400,287,357 shares
Treasury shares	407,397 shares

Contact:

Guillaume Sakuma
Global Head of IR, IR Group
E-mail: ir@santen.com

About Santen

As a specialized company dedicated to ophthalmology, Santen carries out research, development, marketing, and sales of pharmaceuticals, over-the-counter products, and medical devices, and its products now reach patients in over 60 countries.

Toward realizing “WORLD VISION” (Happiness with Vision), the world Santen ultimately aspires to achieve, as a “Social Innovator”, we aim to reduce the social and economic opportunity loss of people around the world caused by eye diseases and defects by orchestrating and mobilizing key technologies and players around the world.

With scientific knowledge and organizational capabilities nurtured over a 130-year history, Santen provides products and services to contribute to the well-being of patients, their loved ones and consequently to society.

For more information, please visit Santen’s website (<https://www.santen.com/en/>).